The impact of antiplatelet and antithrombotic regimen after TAVI,European Journal of Clinical Investigation

当前位置： X-MOL 学术 › Eur. J. Clin. Investig. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The impact of antiplatelet and antithrombotic regimen after TAVI
European Journal of Clinical Investigation ( IF 5.5 ) Pub Date : 2021-06-13 , DOI: 10.1111/eci.13589
Markus Mach _{1,

2} , Victoria Watzal ₁ , Carina Cuhaj ₂ , Waseem Hasan _{2,

3} , Thomas Poschner ₁ , Philipp Szalkiewicz ₁ , Andreas Strouhal ₄ , Christopher Adlbrecht ₄ , Georg Delle-Karth ₄ , Martin Grabenwöger _{2,

5} , Bernhard Winkler ₂

Affiliation

We compared the outcomes and adverse events of TAVI patients based on the discharge and long-term antiplatelet or anticoagulant treatment regimens (single antiplatelet [SAPT] vs. dual antiplatelet [DAPT] vs. anticoagulation [OAC] vs. no treatment [NT]).

中文翻译：